Navigation Links
Shire and TAP Agree to Co-promote LIALDA(TM) (mesalamine), the First Oral Once-Daily Mesalamine For Patients With Active, Mild to Moderate Ulcerative Colitis
Date:3/26/2008

http://www.LIALDA.com

Important Safety Information

LIALDA tablets are indicated for the induction of remission in patients with active, mild to moderate ulcerative colitis. Safety and effectiveness of LIALDA beyond eight weeks have not been established.

LIALDA is contraindicated in patients with hypersensitivity to salicylates (including mesalamine) or to any of the components of LIALDA. Caution should be exercised when treating patients with pyloric stenosis or those allergic to sulfasalazine. Mesalamine has been associated with an acute intolerance syndrome (three percent of patients in clinical trials with mesalamine or sulfasalazine) that may be difficult to distinguish from a flare of inflammatory bowel disease. If acute intolerance syndrome is suspected, prompt withdrawal is required. Mesalamine-induced cardiac hypersensitivity reactions (myocarditis and pericarditis) have been reported.

Reports of renal impairment have been associated with mesalamine medications. In patients with renal impairment, caution should be exercised, and LIALDA should be used only if the benefits outweigh the risks. No information is available for patients with hepatic impairment.

LIALDA is generally well tolerated. The majority of adverse events in the double-blind, placebo-controlled trials were mild or moderate in severity. In clinical trials (N=535), the most common treatment-related adverse events with LIALDA 2.4g/day, 4.8g/day and placebo were headache (5.6 percent, 3.4 percent and 0.6 percent, respectively) and flatulence (four percent, 2.8 percent and 2.8 percent, respectively). Pancreatitis occurred in less than one percent of patients during clinical trials and resulted in discontinuation of therapy with LIALDA.

Notes to Editors

Shire plc

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the speciali
'/>"/>

SOURCE Shire plc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Shire Appoints Sylvie Gregoire President of Human Genetic Therapies Business
2. Shires ELAPRASE(R) (idursulfase) Approved in Japan for the Treatment of Hunter Syndrome
3. Shire Divests Non-Core Product Portfolio to Almirall
4. Correction: Shire plc: Third Quarter 2007 results date notification November 1, 2007
5. David Mott Appointed Non Executive Director at Shire
6. Shire plc: Board Changes
7. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
8. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
9. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
10. Texas Boy Receives Wheelchair From New Hampshire Couples Recently Deceased Granddaughter
11. Shire Engages Palio
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... United States (PRWEB) September 16, 2014 ... Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies is ... This report focuses on the three principal types ... of research and development in cancer immunotherapy (which ... inhibitors, Therapeutic anticancer vaccines and Adoptive cellular immunotherapy. ...
(Date:9/15/2014)... very idea of fibers made of carbon nanotubes is neat, ... , The single-walled carbon nanotubes in new fibers created at ... a process designed by chemist Angel Mart and his colleagues. ... its results this month in the journal ACS Nano ... drawn together into a fiber. , Left to their own ...
(Date:9/15/2014)... DUBLIN , Sept. 15, 2014 Research ... "Whole Exome Sequencing Market by Product, by Services, by Technology, ... their offering. Whole Exome Sequencing (WES) is ... the genome, i.e. the exon. The exome, which is the ... of the total genome and is actually converted into proteins ...
(Date:9/15/2014)... , 15 de septiembre de 2014 La segunda ... a cabo del 12 al 18 de octubre. Como iniciativa ... y de sus compañías miembro s, la IPAW se ... mundial en torno a la colección de fuentes de plasma ... plasma al salvar y mejorar las vidas , Aumento ...
Breaking Biology Technology:Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 2Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 3Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 4Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 5Rice rolls 'neat' nanotube fibers 2Rice rolls 'neat' nanotube fibers 3Global Whole Exome Sequencing (Systems, Kits, Library Preparation, Target Enrichment) Market by Product, by Services, by Technology, by Application - Forecast to 2018 2Global Whole Exome Sequencing (Systems, Kits, Library Preparation, Target Enrichment) Market by Product, by Services, by Technology, by Application - Forecast to 2018 3La International Plasma Awareness Week será una celebración para los donantes 2La International Plasma Awareness Week será una celebración para los donantes 3
... Md., Aug. 18, 2011 The Plasma Protein Therapeutics ... Medicaid Services (CMS) take necessary steps to improve drug ... At last week,s Advisory Panel on Ambulatory ... continued failure by CMS to remove hospitals that purchase ...
... Aug. 18, 2011 Reportlinker.com announces that ... in its catalogue: Global ... http://www.reportlinker.com/p0588171/Global-Genetic-Testing-Market-Analysis.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Genomics In a ... represents a highly attractive segment. Genetic testing ...
... 2011 Poplar Healthcare, a leading laboratory services company, ... the existing entities known as GI Pathology, D-PATH Dermatopathology ... expand," remarks William McDowell, CEO of Poplar Healthcare, "we ... brand to which our individual companies could belong, while ...
Cached Biology Technology:PPTA Urges CMS for Appropriate Hospital Outpatient Reimbursement for Plasma Protein Therapies 2PPTA Urges CMS for Appropriate Hospital Outpatient Reimbursement for Plasma Protein Therapies 3PPTA Urges CMS for Appropriate Hospital Outpatient Reimbursement for Plasma Protein Therapies 4Global Genetic Testing Market Analysis 2Global Genetic Testing Market Analysis 3Poplar Healthcare Forms Parent Company, Launches New Web Site 2
(Date:9/15/2014)... as much as 170 tons, the blue whale is the ... living thing ever seen on Earth. So there,s no way ... larvae, which measure millimeters in length and tip the scales ... so fast, says L. Mahadevan, the Lola England de Valpine ... of Physics. , Using simple hydrodynamics, a team of ...
(Date:9/15/2014)... tip the balance between ridding the body of a ... a report appearing in The Journal of ... viruses cause chronic infections in roughly three-quarters of infected ... diseases including cirrhosis and cancer. A few patients successfully ... CD8 + T cells. The protective effects of ...
(Date:9/15/2014)... Calif. , Sept. 15, 2014  GENiSYSS, ... California , announces the public launch of ... very unique, patented product, combining room temperature, long-term ... the only company to make personal storage of ... Photo - http://photos.prnewswire.com/prnh/20140912/145664   Photo - ...
Breaking Biology News(10 mins):The science behind swimming 2The science behind swimming 3GENiSYSS Launches Website about Easy, Inexpensive Home DNA Storage for Everyone 2
... Ribbons of ultrathin graphene combined with polyurethane paint meant for ... according to scientists at Rice University. The Rice ... developed the compound to protect marine and airborne radars with ... The research was published this week in the ...
... causes diseases like Alzheimer,s, Parkinson,s and Creutzfeldt-Jakob disease. ... lead to the development of new composite materials ... tomorrow, and even make objects invisible. Researchers ... unexpected discovery about amyloid in an article published ...
... 2013Time-lapse movies of a cellular heaven and hell, a crane ... of muscle cells were recognized with the top three awards ... Cell Biology Video Contest for 2013. The awards were ... ASCB Annual Meeting, Sunday , Dec. 14, in New Orleans. ...
Cached Biology News:Graphene nanoribbons an ice-melting coat for radar 2Graphene nanoribbons an ice-melting coat for radar 3Alzheimer substance may be the nanomaterial of tomorrow 2Celldance 2013 video awards, the 'Cell Oscars,' roll out tiny red carpet 2Celldance 2013 video awards, the 'Cell Oscars,' roll out tiny red carpet 3
...
Mouse monoclonal antibody raised against a partial recombinant VRK2. NCBI Entrez Gene ID = VRK2...
Mouse monoclonal antibody raised against a partial recombinant L3MBTL2. NCBI Entrez Gene ID = L3MBTL2...
Mouse polyclonal antibody to BAG2 - BCL2-associated athanogene 2...
Biology Products: